Literature DB >> 12597458

Significance of hepatic preneoplasia in risk identification and early detection of neoplasia.

Peter Bannasch1, Thomas Haertel, Qin Su.   

Abstract

Among the different types of liver tumor, hepatocellular neoplasms predominate by far in both animals and man. Consequently, preneoplastic foci of altered hepatocytes (FAH), preceding both hepatocellular adenomas and carcinomas, represent the most prevalent form of hepatic preneoplasia observed in animals for a long time, and identified in human chronic liver diseases associated with, or predisposing to, hepatocellular carcinomas more recently. Morphological, microbiochemical, and molecular biological approaches in situ revealed striking similarities in specific changes of the cellular phenotype of preneoplastic FAH developing in experimental and human hepatocarcinogenesis, irrespective of whether this was elicited by chemicals, hormones, viruses or radiation. The advantage of using FAH for risk identification (aiming at primary cancer prevention) in long-term and medium-term carcinogenesis bioassays has been well documented, but quantitative morphometric approaches appear to be indispensable for an appropriate evaluation of both bioassays. The detection of phenotypically similar FAH in various animal models and in humans prone to develop or bearing hepatocellular carcinomas favors the extrapolation from data obtained in animals to humans. Moreover, the recently reported frequent finding of FAH in fine-needle biopsies of patients suffering from chronic liver diseases opens new perspectives for secondary prevention of human hepatocellular carcinoma.

Entities:  

Mesh:

Year:  2003        PMID: 12597458     DOI: 10.1080/01926230390173923

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  12 in total

1.  Inhibition of diethylnitrosamine-initiated alcohol-promoted hepatic inflammation and precancerous lesions by flavonoid luteolin is associated with increased sirtuin 1 activity in mice.

Authors:  Bruna Paola Murino Rafacho; Camilla Peach Stice; Chun Liu; Andrew S Greenberg; Lynne M Ausman; Xiang-Dong Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

2.  Glycogenotic hepatocellular carcinoma with glycogen-ground-glass hepatocytes: a heuristically highly relevant phenotype.

Authors:  Peter Bannasch
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

3.  Immune selection during chronic hepadnavirus infection.

Authors:  William S Mason; Sam Litwin; Allison R Jilbert
Journal:  Hepatol Int       Date:  2007-12-14       Impact factor: 6.047

4.  The liver of woodchucks chronically infected with the woodchuck hepatitis virus contains foci of virus core antigen-negative hepatocytes with both altered and normal morphology.

Authors:  Chunxiao Xu; Toshiki Yamamoto; Tianlun Zhou; Carol E Aldrich; Katy Frank; John M Cullen; Allison R Jilbert; William S Mason
Journal:  Virology       Date:  2006-10-31       Impact factor: 3.616

5.  Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice.

Authors:  Sabrina C Wentz; Huangbing Wu; Michele T Yip-Schneider; Matthew Hennig; Patrick J Klein; Judith Sebolt-Leopold; C Max Schmidt
Journal:  J Gastrointest Surg       Date:  2007-11-07       Impact factor: 3.452

6.  Modeling complex decay profiles of hepatitis B virus during antiviral therapy.

Authors:  Harel Dahari; Emi Shudo; Ruy M Ribeiro; Alan S Perelson
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

7.  Transcriptomic responses provide a new mechanistic basis for the chemopreventive effects of folic acid and tributyrin in rat liver carcinogenesis.

Authors:  Aline H Guariento; Kelly S Furtado; Aline de Conti; Adriana Campos; Eduardo Purgatto; Jéssica Carrilho; Elvira Maria Guerra Shinohara; Volodymyr Tryndyak; Tao Han; James C Fuscoe; Sharon A Ross; Frederick A Beland; Igor P Pogribny; Fernando S Moreno
Journal:  Int J Cancer       Date:  2014-02-22       Impact factor: 7.396

8.  Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

Review 9.  Key issues in the modes of action and effects of trichloroethylene metabolites for liver and kidney tumorigenesis.

Authors:  Jane C Caldwell; Nagalakshmi Keshava
Journal:  Environ Health Perspect       Date:  2006-09       Impact factor: 9.031

10.  Comparative histomorphological review of rat and human hepatocellular proliferative lesions.

Authors:  Bob Thoolen; Fiebo J W Ten Kate; Paul J van Diest; David E Malarkey; Susan A Elmore; Robert R Maronpot
Journal:  J Toxicol Pathol       Date:  2012-10-01       Impact factor: 1.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.